Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 40,000 shares at $65.36 ($2.6M) on 2026-04-01, disclosed to the SEC on 2026-04-02.
Scheduled sale ($2.6M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $65.36 | 19,000 | $1.2M | 47.9% |
| 2 | $65.71 | 1,000 | $66K | 2.5% |
| 3 | $64.06 | 15,800 | $1.0M | 39.0% |
| 4 | $64.89 | 4,200 | $273K | 10.5% |
| Total | $64.81 avg | 40,000 | $2.6M | 100% |
| Filing → |
| HALO | SELL | 2026-08-19 | $6.3M | — | Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |